IL288078A - Eltrombopag dosing regimen - Google Patents

Eltrombopag dosing regimen

Info

Publication number
IL288078A
IL288078A IL288078A IL28807821A IL288078A IL 288078 A IL288078 A IL 288078A IL 288078 A IL288078 A IL 288078A IL 28807821 A IL28807821 A IL 28807821A IL 288078 A IL288078 A IL 288078A
Authority
IL
Israel
Prior art keywords
eltrombopag
pharmaceutically acceptable
acceptable salt
tapering
dose
Prior art date
Application number
IL288078A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharmaceuticals Corp filed Critical Novartis Pharmaceuticals Corp
Publication of IL288078A publication Critical patent/IL288078A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL288078A 2019-05-14 2019-05-14 Eltrombopag dosing regimen IL288078A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/032171 WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Publications (1)

Publication Number Publication Date
IL288078A true IL288078A (en) 2025-01-01

Family

ID=67211802

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288078A IL288078A (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Country Status (9)

Country Link
US (1) US20220313663A1 (cg-RX-API-DMAC7.html)
EP (1) EP3968984A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537883A (cg-RX-API-DMAC7.html)
KR (1) KR20220035036A (cg-RX-API-DMAC7.html)
AU (2) AU2019445762A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140137A1 (cg-RX-API-DMAC7.html)
IL (1) IL288078A (cg-RX-API-DMAC7.html)
MX (1) MX2021013971A (cg-RX-API-DMAC7.html)
WO (1) WO2020231407A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150148385A1 (en) * 2012-06-29 2015-05-28 Shionogi & Co., Ltd. Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150148385A1 (en) * 2012-06-29 2015-05-28 Shionogi & Co., Ltd. Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BUSSEL J. ET AL.:, TAPERING ELTROMBOPAG IN PATIENTS WITH CHRONIC ITP: HOW SUCCESSFUL IS THIS AND IN WHOM DOES IT WORK?, 5 December 2015 (2015-12-05) *
CLINICAL TRIALS:, NCT03524612:A STUDY TO ASSESS THE ABILITY OF ELTROMBOPAG TO INDUCE SUSTAINED RESPONSE OFF TREATMENT IN SUBJECTS WITH ITP (TAPER), 9 May 2019 (2019-05-09) *
EUROPEAN MEDICAL AGENCY:, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, 4 April 2016 (2016-04-04) *
EUROPEAN MEDICINES AGENCY, CHMP ASSESSMENT REPORT FOR REVOLADE, 18 May 2010 (2010-05-18) *
GHADAKI B. ET AL.:, SUSTAINED REMISSIONS OF IMMUNE THROMBOCYTOPENIA ASSOCIATED WITH THE USE OF THROMBOPOIETIN RECEPTOR AGONISTS, 3 March 2013 (2013-03-03) *
GONZALEZ PORRAS J. ET AL.:, ELTROMBOPAG IN IMMUNE THROMBOCYTOPENIA: EFFICACY REVIEW AND UPDATE ON DRUG SAFETY, 19 April 2018 (2018-04-19) *
GONZALEZ-LOPEZ T. ET AL.:, SUCCESSFUL DISCONTINUATION OF ELTROMBOPAG AFTER COMPLETE REMISSION IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA, 16 January 2015 (2015-01-16) *

Also Published As

Publication number Publication date
JP2023182667A (ja) 2023-12-26
AU2019445762A1 (en) 2021-12-09
MX2021013971A (es) 2022-04-01
AU2023274065A1 (en) 2023-12-14
JP2022537883A (ja) 2022-08-31
US20220313663A1 (en) 2022-10-06
CA3140137A1 (en) 2020-11-19
WO2020231407A1 (en) 2020-11-19
KR20220035036A (ko) 2022-03-21
EP3968984A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
JP7295305B2 (ja) ループス腎炎の治療のための改善されたプロトコル
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
TWI729022B (zh) 用於治療葡萄膜炎及黃斑水腫之包含il6r抗體的組合物與其使用方法
JP2009511604A (ja) 緑内障の原発性形態および続発性形態を処置するための方法
JP2024530954A5 (cg-RX-API-DMAC7.html)
JP2022184998A (ja) 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
Desideri et al. Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
US9920131B2 (en) Dosage and administration of anti-EGFR therapeutics
JP2021152002A5 (cg-RX-API-DMAC7.html)
WO2020231408A1 (en) Eltrombopag dosing regimen
AU2023274065A1 (en) Eltrombopag dosing regimen
CN107249586A (zh) 用于治疗精神分裂症的伊潘立酮
US20230167189A1 (en) Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
JP2020172471A (ja) ヒト化抗ヒトcd26抗体を含有する医薬組成物
Shah et al. Clinical Trials in Age-related Macular Degeneration-IV
Delaney et al. Emerging treatments for non-infectious uveitis
Dalton et al. Ranibizumab achieves higher BCVA gains for BRVO in COMRADE-B.
INGERMAN et al. Emerging Treatments
Narayanan et al. Corticosteroids: Triamcinolone, Dexamethasone
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf
WO2005082374A1 (en) Predictors for patients at risk for glaucoma from steroid therapy